How to structure an IB (Investigator's Brochure) for regulatory review

Creating a robust Investigator's Brochure (IB) is a critical milestone in the drug development lifecycle, serving as the primary source of information for regulators regarding the safety, quality, and efficacy of a clinical trial. A well-structured IB not only facilitates a smoother regulatory review process but also demonstrates the sponsor's commitment to transparency and scientific rigor. This guide outlines the essential steps to organize an IB that meets global regulatory expectations and ensures a seamless path to approval.

The Foundation: Aligning with ICH E6(R2)

Before diving into specific sections, the overarching structure must be grounded in the International Council for Harmonisation Guideline E6(R2) on Good Clinical Practice. The IB is not merely a collection of data; it is a dynamic document that evolves alongside the trial. It must clearly reflect the current status of the study, including any protocol deviations, unexpected adverse events, or changes in the investigational product. Regulatory authorities expect the IB to provide a comprehensive overview of the clinical trial's design, execution, and emerging results. Therefore, the initial phase involves mapping the existing clinical trial report (CTR) data and safety database to ensure every claim is substantiated by evidence. The document should explicitly state the version history, date of compilation, and the names of the principal investigators and sponsors responsible for its content.

Core Content Requirements and Section Organization

The heart of the IB lies in its detailed content, which typically spans from approximately 30 to 60 pages depending on the complexity of the trial. Regulatory reviewers look for a logical flow that tells the story of the drug's development and the trial's conduct. The standard structure begins with a summary of the clinical trial, followed by detailed descriptions of the investigational product, study design, and subject recruitment. Crucially, the document must include a section dedicated to the adverse events observed during the study. This section requires a granular breakdown of the types, frequencies, and severity of events, along with the relationship of these events to the study drug. Furthermore, the IB must detail the methods used to collect and analyze the data, including the statistical models employed and the population demographics. Each section should be self-contained yet interconnected, allowing a reviewer to understand the full context without needing to cross-reference external documents excessively.

Managing Data Integrity and Quality Control

Ensuring the integrity of the data presented in the IB is paramount for regulatory acceptance. This involves a rigorous quality control process where every piece of information is verified against the source documents and the electronic Clinical Study System (eCSD). Data integrity is not just about accuracy; it is about the reliability of the entire dataset. The IB should include a section specifically addressing the data management plan, detailing how missing data were handled, how outliers were identified, and the criteria used for imputation. Additionally, any interim analyses or early stopping rules that were activated must be clearly documented. If the trial was interrupted or terminated early due to safety concerns or futility, the IB must explain the decision-making process behind these choices. The quality assurance team must sign off on every section, confirming that the data presented has been accurately extracted and formatted according to the study protocol and regulatory requirements.

Dynamic Updates and Communication with Authorities

The IB is a living document that requires regular updates throughout the life of the clinical trial. As new data becomes available, such as the completion of a specific cohort or the emergence of a new safety signal, the IB must be revised promptly. These updates should be communicated to the regulatory authority well in advance of the next submission milestone to avoid delays in the review process. It is also important to maintain version control and ensure that the latest revision is the one under review. If significant changes are made to the trial design or the investigational product, the IB must be updated to reflect these modifications, and the rationale for the changes should be clearly explained. Regular internal audits can help identify gaps in the IB before they become issues during the external regulatory review.

Final Review and Submission Readiness

The final stage involves a comprehensive review by all stakeholders, including the clinical team, safety monitor, and regulatory affairs specialists. This final check ensures that all sections are complete, consistent, and free of errors. The document should be formatted professionally, with clear headings, consistent terminology, and easy-to-read tables and figures. Before submission, the IB should undergo a peer review process where independent experts evaluate the content for completeness and clarity. Once approved, the final IB is ready for submission to the relevant regulatory body, serving as a cornerstone of the clinical trial dossier. By following these structured steps, sponsors can ensure their IB meets the highest standards of regulatory expectation, fostering trust and facilitating a more efficient evaluation of the clinical data.

Checklist for Regulatory Compliance

To ensure the Investigator's Brochure is submission-ready, the following critical elements must be verified:

  • All participant identifiers have been fully redacted in accordance with privacy regulations.
  • The safety section accurately reflects the most recent safety database extract with no lag time.
  • The protocol history includes a complete record of all amendments and their impact on the study.
  • Investigator contact information is up to date for all participating sites worldwide.
  • The document includes a clear disclaimer regarding the study status and pending regulatory decisions.

Related reading